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Available online 7 December 2017Branched-chain amino acids (BCAAs) metabolite, 3-Hydroxyisobutyric acid (3-HIB) has been identiﬁed as a se-
creted mediator of endothelial cell fatty acid transport and insulin resistance (IR) using animal models. To iden-
tify if 3-HIB is a marker of human IR and future risk of developing Type 2 diabetes (T2D), we measured plasma
levels of 3-HIB and associated metabolites in around 10,000 extensively phenotyped individuals. The levels of
3-HIB were increased in obesity but not robustly associated with degree of IR after adjusting for BMI. Neverthe-
less, also after adjusting for obesity and plasma BCAA, 3-HIB levels were associated with future risk of incident
T2D. We also examined the effect of 3-HIB on fatty acid uptake in human cells and found that both HUVEC and
human cardiac endothelial cells respond to 3-HIB whereas human adipose tissue-derived endothelial cells do
not respond to 3-HIB. In conclusion, we found that increased plasma level of 3-HIB is a marker of future risk of
T2D and 3-HIB may be important for the regulation of metabolic ﬂexibility in heart and muscles.oratory, KT
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Insulin resistance (IR) is a common consequence of obesity and the
major driver of the current global epidemic of type 2 diabetes (T2D)
and associated diseases. However, not all obese individuals develop IR
or T2D. Thus, we need reliable and easily measured biomarkers of IR
and risk of future disease in order to initiate early clinical interventions
(Mardinoglu and Nielsen, 2012). IR does not only include fat and carbo-
hydrate metabolism but is also associated with amino acid metabolism.
Circulating levels of branched-chain amino acids (BCAAs), includingH - Royal Institute of
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urg, Sweden.
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ef.ﬁ (A. Stančáková),
),
nr.it (E. Ferrannini),
uef.ﬁ (M. Laakso),
open access article undervaline, leucine and isoleucine, are elevated in obese subjects and a dis-
tinctive metabolic signature related to BCAA catabolism has been re-
vealed through metabolomics proﬁling of obese versus lean subjects
(Newgard et al., 2009). Levels of BCAAs as well as aromatic amino
acids, including tyrosine andphenylalanine, also predict future develop-
ment of T2D independent of age, sex, bodymass index (BMI) and family
history (Wang et al., 2011). However,mechanistic explanations for how
increased BCAAs can cause insulin resistant states remain unclear.
A previous study by Jang et al. (2016) has identiﬁed 3-
hydroxyisobutyrate (3-HIB), a valine metabolite and derived from 3-
hydroxyisobutyryl-coenzyme A by HIBC hydrolase (encoded by Hibch)
(Fig. 1A) as a paracrine regulator of trans-endothelial fatty acid trans-
port in the skeletal muscle in mice. The authors showed that 3-HIB, se-
creted from muscle cells, enhances their fatty acid uptake leading to
increased lipid accumulation and induction of whole-body IR. Inhibiting
synthesis of 3-HIB reduced fatty acid uptake by skeletal muscle micro-
vascular endothelial cells and prevented IR.
However, before concluding that 3-HIB also can contribute to human
disease, theﬁndings need to be validated inman. The human translation
of the experimental data inmice was less convincing. 3-HIB levels were
elevated in the muscle of diabetic db/db mice but only in three of thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Plasma levels of 3-HIB are strongly related to BMI. A) Catabolism of branched-chain amino acids (BCAAs) including valine (val), leucine (leu) and isoleucine (Ile). B) Plasma levels of
metabolites involved in BCAA catabolism in lean and obese subjects in RISC study. The Spearmen correlation of BMI, OGIS and the plasma levels of metabolites involved in BCAA
metabolism before (C) and after eliminating the effect of BMI (D) in the RISC study. Correlation of BMI, IS and the plasma levels of metabolites involved in BCAA metabolism before
(E) and after eliminating the effect of BMI (F) in the METSIM study. G) The plasma level of the metabolites involved in BCAA metabolism in healthy subjects and T2D patients in the
EPIC-Norfolk study. (*P-value b 0.05).
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dividuals (Jang et al., 2016). Furthermore, a positive effect of 3-HIB on
fatty acid uptake in human cells was only shown in HUVEC cells
which are of macrovascular, rather than tissue-related microvascular
origin. Furthermore, to be of clinical predictive value we need to under-
stand if plasma levels of 3-HIB can be used as a risk indicator of IR and
future development of T2D inman. If so,Hibch can be a target for devel-
oping efﬁcient treatment strategies for T2D. To examine this, we ana-
lyzed 3-HIB plasma levels in around 10,000 human subjects and their
relation to future development of T2D. We also examined the effect of
3-HIB on fatty acid uptake by human microvascular endothelial cells
from the adipose tissue and heart as well as by HUVEC macrovascular
cells.2. Materials and Methods
2.1. Plasma Metabolomics Data
The subjects included in this study have been described previously
(Lee et al., 2016; Mardinoglu et al., 2017). Signed informed consent
has been obtained from human subjects in all cohorts, and the study
protocol has been approved by the relevant ethical committees. The
studies were conducted according to standards indicated by the Decla-
ration of Helsinki.
Measurement of plasma levels of metabolites involved in BCAA
metabolism was performed using LC-MS. Brieﬂy, the liquid
chromatography-tandem mass spectrometry (LC-MS/MS) platform
153A. Mardinoglu et al. / EBioMedicine 27 (2018) 151–155was based on aWaters ACQUITY ultraperformance liquid chromatogra-
phy (UPLC) system and a Thermo-Finnigan LTQ mass spectrometer op-
erated at nominal mass resolution, which was equipped with an
electrospray ionization (ESI) source and a linear ion trap (LIT) mass
analyzer. The sample extract was dried and then reconstituted in acidic
or basic LC-compatible solvents, each of which contained 12 or more
injection standards at ﬁxed concentrations.
One aliquot was analyzed using acidic positive ion-optimized
conditions and the other was analyzed using basic negative ion-
optimized conditions in two independent injections using separate ded-
icated columns (Waters UPLC BEH C18-2.1 × 100mm, 1.7 lm). Extracts
reconstituted in acidic conditions were gradient eluted using water
and methanol containing 0.1% formic acid, whereas the basic
extracts, which were also eluted using water/methanol, contained
6.5 mM ammonium bicarbonate. The MS analysis alternated
between MS and data-dependent MS/MS scans using dynamic exclu-
sion, and the scan range was from 80 to 1000m/z. Following log trans-
formation, Welch's two-sample t-test was used to identify levels of
BCAA metabolites that differed signiﬁcantly between the biological
samples.2.2. Fatty Acid Transport in Human Adipose Tissue-and Cardiac-Derived
Endothelial Cells
Fatty acid uptakewasmeasured using the Quencher-Based Technol-
ogy (QBT) Fatty Acid Uptake Assay Kit (Molecular Devices) as reported
(Liao et al., 2005). Brieﬂy, human adipose tissue– and cardiac-derived
microvascular (c-MVEC) (LONZA-CC-7030) or HUVEC (ATCC-CRL-
1730) macrovascular endothelial cells were plated onto a 96-well
black-wall/clear-bottom plate at 10,000 cells/well in endothelial
cell culture media EBM-2. After 20 h, the cells were stimulated with
no additions, 3-HIB (5 mM) or OA (300uM) for 24 h. Cells were then
plasma-deprived for 1 h (3-HIB and OA still included), followed by the
addition of QBT Fatty loading buffer to each well. Kinetic readings
were started immediately with a Tecan Inﬁnite M200 ﬂuorescence
plate reader.2.3. Sampling and Statistical Analysis
Prospective association with incident type 2 diabetes of BCAA-
pathway metabolites were performed in up to 6991 individuals from
the population-based EPIC-Norfolk study, including 693 incident cases
of T2D and 6298 non-cases. EPIC-Norfolk is a prospective cohort study
of over 25,000 individuals living in the Norfolk County in East Anglia
(United Kingdom) at recruitment in 1993–1997 (Day et al., 1999). In
EPIC-Norfolk, BCAA-related metabolites were measured using an
untargeted UPLC-MS/MS platform (DiscoveryHD4® platform -
Metabolon Inc.) in citrated plasma samples collected at baseline as pre-
viously described (Lotta et al., 2016). Before analysis, metabolite levels
reported by Metabolon were ln-transformed, winsorised to 5 SDs and
standardised to a mean of 0 and a standard deviation of 1. Cox
proportional hazards regression with Prentice weighting and robust
standard errors was used to estimate multivariable-adjusted hazard ra-
tios (HRs) for incident type 2 diabetes and their 95% conﬁdence inter-
vals (CI). The levels of blood metabolites at baseline were the
exposure variable in the analysis. Age was used as the underlying
time scale from recruitment to study exit (diagnosis of type 2 diabetes
or censoring) of each participant. Covariates in the association
analysis included age at baseline, sex, experimental batch, BMI, waist
circumference, educational attainment, family history of type 2 diabe-
tes, smoking status, alcohol consumption and self-reported level of
physical activity.
Analyses were conducted using R (https://cran.r-project.org/) and
STATA v14.2 (StataCorp, College Station, Texas 77845 USA).3. Results
3.1. BMI Is a Major Regulator of Plasma BCAA Metabolite Levels
We analyzed the plasma levels BCAAs, branched-chain ketoacids
(BCKAs) including 3-Methyl-2-oxobutyric acid (3-MOB), 3-Methyl-2-
oxopentanoic acid (3-MOP) and 4-Methyl-2-oxopentanoic acid (4-
MOP) as well as 3-HIB in up to 10,000 individuals available to the IMI/
EMIF collaborative study. First, we analyzed plasma of 955 subjects in-
volved in the Relationship between Insulin Sensitivity and Cardiovascu-
lar Disease (RISC) Study (Hills et al., 2004) using the validated oral
glucose insulin sensitivity (OGIS) index (Mari et al., 2001) as a marker
of glucose clearance. We measured the plasma levels of these metabo-
lites in lean (BMI b 25) and obese (BMI N 30) subjects and found that
the levels of 3-HIB as well as the other measured BCAA metabolites
were signiﬁcantly (P-value b 0.05) upregulated in obese compared to
lean subjects (Fig. 1B). Spearman's correlation coefﬁcients (r) between
the BMI, OGIS and plasma levels of these metabolites also showed sig-
niﬁcant (P-value b 0.05) correlations between each other (Fig. 1C).
We also performed partial correlation analysis and found the correla-
tions between the plasma levels of 3-HIB and OGIS to be markedly
weakened by adjusting for BMI (Fig. 1D).
To further validate these data,we examined the BCAAmetabolites in
plasma samples from randomly selected 992 non-diabetic individuals
who participated in a 6-year follow-up in the cross-sectional
population-based METabolic Syndrome In Men (METSIM) Study
(Stancakova et al., 2009). Subjects involved in the METSIM study were
extensively phenotyped and the validated Matsuda insulin sensitivity
index (ISI) (Matsuda andDeFronzo, 1999)was used as amarker of insu-
lin sensitivity (IS). We measured the plasma levels of 3-HIB as well as
the other BCAA metabolites and found the plasma levels signiﬁcantly
correlated with BMI and the Matsuda ISI (Fig. 1E). After adjusting for
the effect of BMI, the correlation between the plasma levels of 3-HIB
and the Matsuda ISI was weakened and became borderline signiﬁcant
(Fig. 1F). In both of these European cohorts, we found that OGIS and
Matsuda ISI had signiﬁcantly higher correlations with valine, which is
catabolized to 3-HIB, compared to the correlations with 3-HIB both be-
fore and after adjusting for the effect of BMI. Taken together, these re-
sults support 3-HIB as a marker of BMI and associated degree of IS.
3.2. Association of BCAA Metabolite Levels With Incident T2D
It has been shown that circulating levels of BCAAs are associated
with risk of future T2D in non-diabetic individuals from the general
population and that genetic risk markers for T2D also identify individ-
uals with elevated BCAA levels (Lotta et al., 2016; Xu et al., 2013). In
this context, we studied the association of baseline plasma 3-HIB levels
with incident T2D in up to 6991 individuals from the population-based
EPIC-Norfolk study (including 693 incident cases of T2D and 6298 non-
cases) using weighted Cox regression. Baseline 3-HIB levels were in-
deed associated with incident T2D, but the association was greatly at-
tenuated after adjusting for BMI and waist circumference (WC): a
marker of abdominal obesity (Table 1). The association was further at-
tenuated after adjusting for baseline BCAAs levels (Table 1).
Plasma levels of 3-HIB were signiﬁcantly (P-value b 0.05) increased
in subjects with T2D and so are the levels of other measured BCAA me-
tabolites (Fig. 1H). In order to understand if the level of 3-HIB is depen-
dent on the level of valine in subjects with T2D, we calculated the
correlation between the levels of these two BCAA metabolites and ob-
served a signiﬁcant (P-value b 0.05) correlation (r = 0.36) in the
EPIC-Norfolk study. Similarly, we calculated the correlations between
the levels of 3-HIB and valine, leucine and isoleucine in the METSIM
study and found signiﬁcantly higher correlations between3-HIB and va-
line (r= 0.262) compared to leucine (r = 0.213) and isoleucine (r =
0.156). Taken together, we conclude that 3-HIB plasma levels are in-
creased in subjects with T2D, like other BCAAs, and 3-HIB plasma levels
Table 1
Association of baseline 3-HIB levels with incident T2D in the EPIC-Norfolk study. In Basic model, the adjustment was made
for study speciﬁc covariates including age at baseline, experimental batch, BMI,waist circumference, educational attainment,
family history of type 2 diabetes, smoking status, alcohol consumption and self-reported level of physical activity to account
for confounding effects of other risk factors of T2D.
Basic model 1.29 (1.20, 1.40)
Basic model + BMI 1.20 (1.11, 1.30)
1.66 .75 1.33 1.5
1.20 (1.11, 1.30)Basic model + WC
1.20 (1.11, 1.29)Basic model + BMI + WC
1.12 (1.03, 1.23)Basic model + BMI + WC + BCAAs
Model HR (95% CI) p-value
4.5 x 10-11
8.3 x 10-06
4.9 x 10-06
5.9 x 10-06
0.0095
154 A. Mardinoglu et al. / EBioMedicine 27 (2018) 151–155are associated with future development of incident T2D. However, the
association with IR in man is confounded by the association with BMI
and, thus, amount of adipose tissue.
3.3. 3-HIB Does Not Enhance Fatty Acid Transport in Adipose Tissue-
Derived Endothelial Cells
Since BMI and amount of adipose tissuewere clearly correlatedwith
3-HIB levels, we asked if the adipose tissue is a target for 3-HIB to in-
crease fatty acid uptake and ﬂux as shown in mouse skeletal muscle
andHUVEC cells by Jang et al. (2016).We pre-incubated human adipose
tissue-derivedmicrovascular endothelial cells with concentrations of 3-
HIB used by Jang et al. (2016) for up to 24 h but saw no increase in fatty
acid uptake while oleic acid, as expected, increased uptake (Fig. 2A).
However, both human HUVEC and cardiac microvascular endothelial
cells responded to 3-HIB with increased fatty acid uptake (Fig. 2B).
Thus, 3-HIB is not a uniform enhancer of peripheral tissue fatty acid up-
take in human endothelial cells but the effect in cardiac-derived endo-
thelial cells indicates that 3-HIB can be involved in regulating both
skeletal and heart muscle fatty acid uptake which can make it an inter-
esting metabolic target of peripheral lipotoxicity in man.
4. Discussion
From a clinical point of view, it is important to early identify bio-
markers inmanwhich are associatedwith risk of developing future dis-
ease. This allows the implementation of intervention procedures and
can prevent the development of incident disease. In a previous publica-
tion, Jang et al. (2016) showed that 3-HIB is secreted by mouse skeletal
muscles genetically engineered to increase PGC1 expression and that 3-
HIB increases skeletal muscle fatty acid uptake and induces insulin re-
sistance in mice. We here asked if plasma levels of 3-HIB is a potentialFig. 2. Fatty acid transport in humanmicrovascular and cardiac-derived endothelial cells. A) Fat
effect of preincubating the cells for up to 24 h with 5 mM 3-HIB while preincubation with oleic
derived endothelial cells was signiﬁcantly increased by 3-HIB.candidate for identifying future risk of T2D. Our study documented
the importance of having access to large prospective databases of indi-
viduals with extensively characterized phenotypes and with clinical
outcomedata in order to evaluate the importance of potential novel bio-
markers and mechanisms of disease.
Our results showed that plasma 3-HIB levels are increased in indi-
viduals with IR but also that obesity is an important confounding factor
for this relationship. Indeed, elevated 3-HIB levels were associated with
future development of T2D, but this risk was markedly reduced when
BMI was taken into account. Thus, our data in man showed that plasma
levels of 3-HIB are strongly inﬂuenced by not only skeletal muscle but
also by amount of adipose tissue. This was further supported by the
data where 3-HIB-associated degree of insulin sensitivity was of less
prominence when BMI was accounted for. In fact, recent studies have
shown that activity of BCAAmetabolism is high in the adipose tissue, ac-
tually higher than in skeletal muscles per unit weight in mice (Herman
et al., 2010). It has also been shown that obesity leads to decreased ca-
tabolism of BCAAs in the adipose tissue in man although this has been
questioned (Lackey et al., 2013; Mardinoglu et al., 2014). Important
data in this respect come from studies in monozygotic twins discordant
for obesity showing increased plasma levels of BCAA in the obese com-
pared to the non-obese twin. The obese twin had lower mitochondrial
DNA copy number as well as downregulated levels of key markers of
BCAA oxidation in the adipose tissue (Pietilainen et al., 2008). These
data, together with our current ﬁndings in very large human cohorts,
raise the importance of the adipose tissue for BCAA metabolism and
plasma 3-HIB levels.
To examine if 3-HIB also regulates fatty acid transport in human ad-
ipose tissue, we examined its effect in human adipose tissue-derived
endothelial cells but saw no such effect. However, similar to the data
by Jang et al. (2016), we also found positive effects of 3-HIB on fatty
acid transport in humanHUVEC cells. Interestingly, 3-HIB also increasedty acid transport in human adipose tissue-derivedmicrovascular endothelial cells show no
acid (OA) (300 μM) increased fatty acid uptake. B) However, fatty acid uptake by cardiac-
155A. Mardinoglu et al. / EBioMedicine 27 (2018) 151–155fatty acid transport in human cardiac-derived endothelial cells which
suggests that both skeletal muscle and heart fatty acid transport are
under regulation of 3-HIB. The fact that 3-HIB did not increase uptake
in the adipose tissue but did in muscle/heart endothelial cells raises
the question if 3-HIB may be a regulator of metabolic ﬂexibility in mus-
cle tissues in man and where increased fatty acid uptake is associated
with reduced carbohydrate metabolism. Such an effect would then
also be important for the development of whole-body IR and reduced
peripheral glucose uptake.
Amajor strength of this study is the access to large European human
cohorts with extensive phenotyping and with prospective follow-up to
identify future development of incident disease. This is accomplished by
the EU/IMI-funded large collaborative project EMIF where one focus is
to identify novel markers of obesity-associated metabolic complica-
tions. A weakness of the study is that the databases only include
European cohorts and validation of these data in other ethnic groups
is required.
Taken together, 3-HIB is likely to be released by both skeletal mus-
cles and the adipose tissue in man and elevated levels reﬂect the com-
pound effect of these tissues. However, 3-HIB is also marker of future
risk of T2D and may be important for the regulation of metabolic ﬂexi-
bility in heart and muscles.
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